Rut Porta

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rafael Rosell, Teresa Morán, Cristina Queralt et al. · New England Journal of Medicine · 2009 · 2.4K citations · Full text

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Rafael Rosell, Urania Dafni, Enriqueta Felip et al. · The Lancet Respiratory Medicine · 2017 · 182 citations

Medicine, Pathology, Immune Checkpoint Inhibitor +6

Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75

Teresa Puig, Alejandro Vázquez‐Martín, Joana Relat et al. · Breast Cancer Research and Treatment · 2007 · 115 citations

Lipid Synthesis, Biochemistry, Lipid Nutrition +10

Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism

Li Yang, Yuhui Huang, Rut Porta et al. · Cancer Research · 2006 · 114 citations · Full text

Profound Reduction, Inflammatory Lung Disease, Immunology +19